MDCXW — Medicus Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1997296 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -8,597,077 | -9,042,143 | 7,426,911 | 6,365,624 | 5,999,017 |
| Dec 2025 | 0 | — | -7,790,600 | -8,184,411 | 10,061,377 | 8,705,218 | 10,024,066 |
| Sep 2025 | 0 | — | -15,426,340 | -15,981,312 | 9,977,661 | 8,662,091 | 10,782,551 |
| Jun 2025 | 0 | — | -6,016,088 | -6,176,084 | 11,934,628 | 9,669,546 | 8,685,918 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,805,463
Investing CF
$0
Financing CF
$35,005,835
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-73,390,261
Inventory
—
Receivables
$14,000
ST Investments
—
EBIT TTM
$-37,900,627
Pretax Income TTM
$-39,384,264
Interest Exp TTM
$1,179,805
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,359,302 | -35,444,215 | 10,061,377 | 10,024,066 | — | -22,776,769 |
| Dec 2024 | 0 | -11,180,902 | -11,155,516 | 5,646,878 | 2,512,174 | — | -10,247,231 |
| Dec 2023 | 0 | -2,658,365 | -5,314,765 | 1,893,057 | 781,609 | — | -4,158,264 |
| Dec 2022 | 0 | -978,416 | -1,692,382 | 282,652 | 12,480,684 | — | -1,057,103 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.02T | $1148.84 | — |
| JNJ | JOHNSON & JOHNSON | $617.78B | $256.35 | — |
| ABBV | AbbVie Inc. | $443.36B | $250.94 | — |
| MRK | Merck & Co., Inc. | $321.57B | $130.20 | — |
| NVSEF | NOVARTIS AG | $301.30B | $158.52 | — |
News headlines (Yahoo Finance, 1h cache)
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
2026-08-01 18:00 · Yahoo
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
2026-07-31 13:24 · Yahoo
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
2026-07-31 11:30 · Yahoo
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
2026-07-31 11:15 · Yahoo
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome
2026-07-27 16:07 · Yahoo
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
2026-07-27 13:34 · Yahoo
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
2026-07-27 12:17 · Yahoo
Medicus Pharma CEO details Teverelix progress – ICYMI
2026-07-18 16:24 · Yahoo
Medicus Pharma advances Phase 2 study following FDA and IRB feedback
2026-07-17 16:48 · Yahoo
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
2026-07-16 12:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.